The second paper from #ASCO2022 #ASCO22 that I break down
This is one of the most technical papers I breakdown on the channel
CT DNA used to omit chemo in Stage II colon cancer
Read the book Malignant if you learn from this
Watch the YouTube Figures https://youtu.be/QxOBIi7I2BU

4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com

Science & Medicine

Natural Sciences

Social Sciences

Medicine

Patient advocates, Pharma funding, and is MRD a suitable endpoint

Patient advocates funded by Pharma

FDA makes MRD the basis for AA

Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".

Beta Blockers After Heart Attacks Don't Work

Blood based and Stool DNA colon cancer screening - Two NEJM papers

Another flawed study Keynote 564. Pembro in adjuvant RCC

4.63 - ASCO22 - DYNAMIC - Can CT DNA Allow us to Give Less Chemo in Stage II Colon Cancer

Download our free app to listen on your phone